Pediatric cancer patients are at increased risk of subsequent malignant neoplasms (SMNs). However, little is known about the contribution of hematopoietic SCT (HSCT) to the development of SMNs. The objective of this study was to compare the incidence of SMNs in a population cohort of childhood cancer survivors treated with and without HSCT. A cohort of 7986 children (age 0-14 years) diagnosed with cancer in the province of Ontario, Canada between 1985 and 2009 was identified in POGONIS (Pediatric Oncology Group of Ontario Networked Information System), a population-based active cancer registry, and linked to a clinical HSCT database. Among this cohort, 796 patients had an HSCT as part of their primary treatment. Of the 375 allogeneic HSCT patients, 14 (3.7%) developed a SMN at a median follow-up of 12.3 years (range: 2.0-22.9 years). Of the 421 autologous HSCT patients, 8 (1.9%) developed a SMN at a median of 4.5 years (range: 1.3-14.3 years). Of the 7190 patients who did not receive an HSCT, 160 (2.2%) developed a SMN at a median follow-up of 6.8 years (range: 0.0-24.9 years). The 15-year cumulative incidence of SMN was 3.1% among the allogeneic HSCT group, 2.5% among the autologous group and 2.3% in the non-HSCT group. The cumulative incidence curves for the allogeneic HSCT and non-transplant groups only diverged after~15 years from primary diagnosis. Our findings further corroborate the observation that children who undergo allogeneic HSCT are at a significantly increased risk of developing SMN compared with pediatric cancer survivors treated without HSCT.
INTRODUCTION
Autologous and allogeneic hematopoietic SCTs (HSCTs) are used increasingly as part of multimodal therapy for childhood malignancies.
1 Improvements in survival rates of patients transplanted for a malignancy have led to an increased focus on decreasing long-term morbidity and mortality. 2 Much of the research that has identified long-term complications after HSCT has been carried out in adult patient populations or combinations of adults and children where adults represent a large proportion of the patients. Survival and other outcomes observed in these cohorts may not reflect the expected outcomes among patients transplanted during childhood.
A significant and often fatal late effect after HSCT is the development of a subsequent malignant neoplasm (SMN). Post-transplant SMNs are generally classified into three categories: (1) hematological malignancies, mainly treatment-related myelodysplastic syndrome and AML (t-MDS/AML); (2) solid tumors; and (3) lymphoma, including post-transplant lymphoproliferative disease (PTLD). 3 In contrast to the late presentation of t-MDS/ AML and solid tumors, PTLD usually occurs within the first year after HSCT. 4, 5 Studies that focus exclusively on long-term cancer survivors often miss PTLD given the time frame in which it occurs.
Few studies have focused specifically on the incidence of post-HSCT SMNs in pediatric populations. 4, [6] [7] [8] [9] Those studies that report on pediatric populations consistently report an inverse relationship between age at transplantation and risk of post-HSCT SMN. 4, 6, 8 However, little is known about the independent contribution of HSCT to the development of SMNs. It is important to characterize and compare the risk of developing SMN in children with malignancies treated with and without HSCT to understand any differences in risk. The objectives of our study were to describe the incidence of SMNs in a population-based cohort of childhood cancer patients treated with autologous and allogeneic HSCT compared with patients treated without HSCT, and to examine the timing of SMN development and other factors associated with the development of SMNs after HSCT.
PATIENTS AND METHODS Patients
The cohort was identified from the Pediatric Oncology Group of Ontario Networked Information System (POGONIS) database, an active pediatric cancer registry administered by the Pediatric Oncology Group of Ontario (POGO). POGONIS collects detailed information for all cases of childhood cancer in Ontario, including demographic, diagnostic and treatment information, and patient outcomes. Pediatric HSCT services are centralized in the province and virtually all HSCTs are performed at the Hospital for Sick Children (SickKids). Therefore, HSCT details were verified and augmented through a linkage of POGONIS with the SickKids BMT database. The cohort consisted of all individuals age 0-14 years who were residents of Ontario at the time of their primary cancer diagnosis and were diagnosed and treated at one of the five tertiary pediatric oncology centers in the province (SickKids, Children's Hospital of Eastern Ontario, Children's Hospital at the London Health Sciences Centre, Kingston General Hospital and McMaster Children's Hospital). Over 98% of children aged 0-14 years are treated at one of these centers and captured in POGONIS.
All eligible subjects were diagnosed with a primary malignancy between 1 January 1985 and 31 December 2009. The HSCT cohort encompassed a subset of patients within the total cohort who underwent an HSCT at SickKids before the age of 19 years as part of their therapy. All patients were followed to the earliest of the development of a SMN, death or December 2012. SMNs that developed within the pediatric age range (before 19 years) that were diagnosed and/or treated at one of the five tertiary pediatric Abbreviations: CNS = central nervous system; HSCT = hematopoietic SCT; SNS = sympathetic nervous system. SMN after HSCT among pediatric cancer patients JD Pole et al oncology centers were captured by POGONIS. SMNs that were diagnosed outside of a tertiary pediatric centre, often in late adolescence or adulthood (aged ⩾ 15 years), were identified through record linkage with the Ontario Cancer Registry. The Ontario Cancer Registry is a legally mandated cancer registry that requires all Ontario hospitals to submit pathology reports, electronic patient records, electronic hospital discharge records and electronic reports of deaths for both adults and children with any mention of cancer. 10, 11 For all registrants in POGONIS, we obtained data on any cancers identified in the Ontario Cancer Registry. Potential SMNs were reviewed manually by two experienced pediatric clinical oncologists (MLG, PCN) and a cancer epidemiologist (JDP) to verify the accuracy of the data and the true incidence of cases of SMNs. Based on reported dates of the primary diagnosis and the date of the first HSCT, SMNs that developed after HSCT were identified.
Treatment information
Treatment-related information was ascertained from POGONIS. Only treatment received for the primary cancer diagnosis (including HSCT conditioning) was considered. Alkylating agent doses were converted to a CY equivalent dose using the methods of Green et al. 12 and were categorized into a four-level variable based on total dose in mg/m 2 : 0, 40-o4000, ⩾ 4000-o8000 and ⩾ 8000. Exposure to radiotherapy was categorized into four mutually exclusive categories: no radiotherapy, only non-TBI, only TBI as part of the conditioning regimen for HSCT and received both non-TBI and TBI. When considering radiation exposure in the autologous HSCT group, patients who received TBI with or without localized radiation were classified in the same group owing to a small number of patients in this category. HSCT donor type was categorized into autologous, allogeneic using related donors and allogeneic using unrelated donors (living unrelated or cord blood stem cells).
Statistical analysis
All statistical analyses were performed using SAS 9.2 (SAS, Cary, NC, USA). The number of person-years at risk was calculated for the entire cohort from the date of diagnosis until the first of SMN diagnosis, death or last follow-up (31 December 2012). For the small number of patients where a SMN developed before HSCT, the patient was censored at the time of SMN. A cumulative incidence curve for the development of SMN for both HSCT and non-HSCT patients was generated with death treated as a competing risk using the CUMINCID macro from the SAS autocall library.
Standardized incidence ratios were estimated by calculating the ratio of the observed number of SMN to the expected incident cancers, derived from age-and sex-specific Ontario population cancer incidence data from Statistics Canada. 13, 14 Nonparametric estimates of the survivor function were generated, stratified by transplant status (HSCT versus non-HSCT). The HSCT group was further stratified by HSCT type (allogeneic HSCT versus autologous HSCT). Separate models that examined factors associated with the development of post-HSCT SMN were developed for the allogeneic and autologous groups with the comparison group for each model being those treated without HSCT. These models assessed the independent effects of multiple factors on the risk for posttransplant SMN, including HSCT type, age at primary cancer diagnosis, sex, CY equivalent dose and receipt of radiotherapy.
This work received research ethics board approval from the University of Toronto and the Hospital for Sick Children.
RESULTS
The cohort comprised 7986 pediatric cancer patients (age 0-14 years old) diagnosed in Ontario between 1985 and 2009. Of these, 796 (10.0%) were treated with HSCT (375 allogeneic, 421 autologous). Table 1 presents the demographic characteristics of the cohort, stratified by HSCT status. As expected, the distribution of primary diagnoses for the HSCT group differed from that of the non-HSCT group. Although the proportion of ALL was similar in the HSCT and non-HSCT groups (23.4% versus 25.8%), the proportion of AML was much larger in the HSCT group than in the non-HSCT group (22.1% versus 2.8%). Neuroblastoma patients comprised a larger proportion of the HSCT group (22.0 compared with 5.5%).
Overall, 22 patients (2.8%) of childhood cancer patients treated with HSCT developed a SMN at a median of 9.4 years (range: 1.3-22.7 years) from diagnosis. Among survivors treated without HSCT, 160 patients (2.2%) developed a SMN at a median of 6.8 years (range: 0.0-24.9 years). Table 2 displays the distribution of SMNs among patients treated with HSCT, stratified by HSCT type. Of the 375 patients who underwent allogeneic HSCT, 14 (3.7%) developed a SMN at a median of 12.3 years (range: 2.0-22.7 years). Among all allogeneic transplant patients, the standardized incidence ratio for the development of a SMN was 15.7 (95% confidence interval (CI): 8.6-25.0). Eleven (78.6%) of the SMNs were solid tumors (including two central nervous system tumors), and 2 (14.3%) were lymphomas (including one incidence of PTLD). The most common SMN in the allogeneic group was thyroid carcinoma. Four of the patients who developed a SMN died (28.7%). Patients who underwent allogeneic HSCT were 4.9 times more likely to have a history of relapse and 2.2 times more likely to be receive alkylating agent therapy compared with the non-HSCT group. Table 3 provides the results of the stratified models examining factors associated with the development of SMN among allogeneic and autologous HSCT patients. In the stratified models, none of HSCT donor relationship, age at diagnosis, sex, CY equivalent dose or radiotherapy exposure was significantly predictive of the development of a SMN in patients treated with an allogeneic HSCT ( Table 3) .
Of the 421 patients who underwent autologous HSCT, 8 (1.9%) developed a SMN at a median of 4.5 years (range: 1.3-14.3 years). Among all autologous transplant patients, the standardized incidence ratio for the development of a SMN was 8.0 (95% CI: Abbreviations: CNS = central nervous system; MDS = myelodysplastic syndrome; NOS = not otherwise specified.
3.4-14.5). Four patients developed MDS/leukemia (2 MDS, 1 AML, 1 ALL) and four patients developed solid tumors (2 carcinoma, 1 hemangiosarcoma, 1 osteosarcoma). Patients who underwent autologous HSCT were 3.3 times more likely to have a history of relapse and 2.3 times more likely to be receive alkylating agent therapy compared with the non-HSCT group. Central nervous system tumors and lymphomas were not observed in this patient group. Among the autologous HSCT patients none of: age at diagnosis, sex or radiotherapy exposure was significantly predictive of the development of a SMN (Table 3 ). The 15-year cumulative incidence of SMNs was 2.3% (95% CI: 2.0-2.8) among the non-HSCT group, 3.1% (95% CI: 1.6-6.1) among the allogeneic HSCT group and 2.5% (95% CI: 1.2-5.1) among the autologous HSCT group (Figure 1) . The cumulative incidence curves only begin to diverge at 15 years from primary diagnosis. Overall, the cumulative incidence is statistically significantly different between the non-HSCT and allogeneic group (P-value o 0.01) but not between the autologous group and the non-HSCT group (P-value = 0.41).
DISCUSSION
The risk of developing a SMN in our population-based study was found to be statistically higher in children treated with allogeneic HSCT for malignancy than those treated with autologous HSCT or without HSCT. The cumulative incidence of SMN at 15 years was Figure 1 . Cumulative incidence of subsequent malignant neoplasm since primary diagnosis by hematopoietic SCT type.
3.1% versus 2.5% and 2.3%, respectively. Differences in the cumulative incidence of SMN between the non-HSCT, allogeneic and autologous groups are only apparent 15 years from primary diagnosis. This confirms that pediatric patients who undergo allogeneic HSCT are at a significantly increased risk of developing post-transplant SMNs, and that the incremental risk only becomes evident with prolonged follow-up from transplantation. Despite the higher incidence and increased risk of SMN in the allogeneic transplant group, the 15-year cumulative incidence of SMN in these patients was lower than that reported previously. The reported rate in the literature ranges from 6.1 to 12.8%. 4, 6, 8, [15] [16] [17] This difference might be attributable to the fact that our cohort was strictly pediatric. Comparable rates to those observed in our study were reported in a single study of pediatric and adults survivors of allogeneic transplant (15-year incidence of 2.2%). 6 Only one case of PTLD case was identified. This is in sharp contrast to previous studies that have reported 30-40% of the post-HSCT SMNs as PTLD. [4] [5] [6] 15, 18 Nearly 60% of the post-HSCT PTLD identified in the literature 6, 15 occurs after HSCT for nonmalignant diseases. Therefore, the low incidence in this cohort can largely be attributed to including only patients who underwent HSCT for a malignant indication. We only observed five case of MDS/secondary leukemia after HSCT. One of these secondary leukemias developed in the allogeneic transplant group and therefore it is possible it could have arisen in the donor cell. Still, this low rate might be related to the young age at transplantation as older age carries an increased risk of secondary AML. 15 More than half of the observed SMNs were solid tumors. In previous studies, this was the only category of malignancy that did not plateau by 20 years. 6 The increased risk of subsequent solid malignancies among patients treated with allogeneic HSCT may be driven largely by therapeutic exposures. A history of relapse (and subsequent need for more chemotherapy) was 4.9 times more common among the allogeneic HSCT group compared with the non-HSCT group. Children treated with allogeneic HSCT were more than 2.2 times more likely to have received alkylating agent therapy, and the average cumulative dose of alkylating agents was higher among the allogeneic HSCT group compared with the non-HSCT group. Likewise, exposure to radiotherapy was 2.4 times higher in the allogeneic HSCT group compared with the non-HSCT group. Alkylating agents and TBI are common elements of HSCT conditioning and both have been linked to a risk of solid tumors in prior studies. 15, 17 These tumors often have a long latency period, as reflected in the late divergence of the incidence curves in the allogeneic HSCT vs non-HSCT/autologous HSCT groups. Curtis et al. 8 reported that children younger than 10 years of age are at increased risk of thyroid and brain tumors after allogeneic HSCT. Similarly, Cohen et al. 19 noted that the risk of developing secondary thyroid carcinomas after HSCT is higher in younger age groups. The observation that the time between HSCT and the diagnosis of a secondary thyroid cancer is short compared with other solid tumors, particularly in children, suggests a distinct more aggressive neoplastic mechanism. 19 In our cohort of HSCT patients, secondary thyroid carcinoma developed at a median of 13.5 years (range: 4.9-22.7 years), while for other solid cancers the time to development was 13.8 years (range: 1.3-17.3 years).
No statistically significant risk factors for the development of SMNs were identified in the allogeneic HSCT group. Similarly, in a study by Baker et al., 6 no association between exposure to TBI and the risk of post-transplant solid tumors was noted. This may be attributed to the fact that the majority of patients in their cohort received TBI, making it harder to detect a difference. The Childhood Cancer Survivor Study suggests that the risks of developing SMNs associated with radiotherapy shows distinct dose-response curves for different SMN diagnoses. 20 Among autologous HSCT patients, 50% of SMNs were solid tumors. This proportion is similar to that reported by the Center for International Blood and Marrow Transplant Research. 9 The
Center for International Blood and Marrow Transplant Research reported on a pediatric cohort treated with autologous HSCT and had a 10-year incidence for SMN of 2.6%. Similar to our study there were no associations between SMN risk and age, gender and diagnosis. 9 Although this study was population-based and did not rely on patient recall, the study does have several limitations. Patients who were treated in Ontario but moved out of the province would not have their SMNs capture by the Ontario Cancer Registry. Using data available from Statistics Canada, out-migration for the Ontario population aged 0-49 years from 1985 to 2013 has averaged 0.6% per annum and peaks in the 25-29 year age range at an average of 1.3% per annum. 21, 22 Therefore, we may have underestimated the number of SMNs, although we expect very few such cases. As a consequence of the small number of SMNs in our cohort, further subanalysis or the inclusion of additional factors related to the development of SMNs was not possible. As data regarding GVHD is not collected routinely by any of the registries used for this study, it was therefore not considered in the analysis, even though it has been identified as a risk factor is some studies. 7, 8, 17 The findings of our study further corroborate the observation that pediatric patients who undergo allogeneic HSCT are at a significantly increased risk of developing post-transplant SMNs. Life-long surveillance for SMNs is required. Future studies should focus on assessing the potential for less toxic treatment regimens in order to reduce the incidence of therapy-related SMNs.
